|
1
|
Fearon K, Strasser F, Anker SD, Bosaeus I,
Bruera E, Fainsinger RL, Jatoi A, Loprinzi C, MacDonald N,
Mantovani G, et al: Definition and classifi cation of cancer
cachexia: An international consensus. Lancet Oncol. 12:489–495.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Argilés JM, Busquets S, Stemmler B and
López-Soriano FJ: Cancer cachexia: Understanding the molecular
basis. Nat Rev Cancer. 14:754–762. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Evans WJ, Morley JE, Argilés J, Bales C,
Baracos V, Guttridge D, Jatoi A, Kalantar-Zadeh K, Lochs H,
Mantovani G, et al: Cachexia: A new definition. Clin Nutr.
27:793–799. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bilir C, Engin H, Can M, Temi YB and
Demirtas D: The prognostic role of inflammation and hormones in
patients with metastatic cancer with cachexia. Med Oncol.
32:562015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Vaughan VC, Martin P and Lewandowski PA:
Cancer cachexia: impact, mechanisms and emerging treatments. J
Cachexia Sarcopenia Muscle. 4:95–100. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tisdale MJ: Mechanisms of cancer cachexia.
Physiol Rev. 89:381–410. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fearon KC, Glass DJ and Guttridge DC:
Cancer cachexia: Mediators, signaling, and metabolic pathways. Cell
Metab. 16:153–166. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Schcolnik-Cabrera A, Chávez-Blanco A,
Domínguez-Gómez G and Dueñas-González A: Understanding tumor
anabolism and patient catabolism in cancer-associated cachexia. Am
J Cancer Res. 7:1107–1135. 2017.PubMed/NCBI
|
|
9
|
Li H, Malhotra S and Kumar A: Nuclear
factor-kappa B signaling in skeletal muscle atrophy. J Mol Med.
86:1113–1126. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rhoads MG, Kandarian SC, Pacelli F,
Doglietto GB and Bossola M: Expression of NF-kappaB and IkappaB
proteins in skeletal muscle of gastric cancer patients. Eur J
Cancer. 46:191–197. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wysong A, Couch M, Shadfar S, Li L,
Rodriguez JE, Asher S, Yin X, Gore M, Baldwin A, Patterson C, et
al: NF-κB inhibition protects against tumor-induced cardiac atrophy
in vivo. Am J Pathol. 178:1059–1068. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tuorkey MJ: Molecular targets of luteolin
in cancer. Eur J Cancer Prev. 25:65–76. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Weng Z, Patel AB, Vasiadi M, Therianou A
and Theoharides TC: Luteolin inhibits human keratinocyte activation
and decreases NF-κB induction that is increased in psoriatic skin.
PLoS One. 9:e907392014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Merriman RL, Shackelford KA, Tanzer LR,
Campbell JB, Bemis KG and Matsumoto K: Drug treatments for
metastasis of the Lewis lung carcinoma: lack of correlation between
inhibition of lung metastasis and survival. Cancer Res.
49:4509–4516. 1989.PubMed/NCBI
|
|
15
|
Au ED, Desai AP, Koniaris LG and Zimmers
TA: The MEK-inhibitor selumetinib attenuates tumor growth and
reduces IL-6 expression but does not protect against muscle wasting
in Lewis lung cancer cachexia. Front Physiol. 7:6822017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chen X, Wu Y, Yang T, Wei M, Wang Y, Deng
X, Shen C, Li W, Zhang H, Xu W, et al: Salidroside alleviates
cachexia symptoms in mouse models of cancer cachexia via activating
mTOR signalling. J Cachexia Sarcopenia Muscle. 7:225–232. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Todorov P, Cariuk P, McDevitt T, Coles B,
Fearon K and Tisdale M: Characterization of a cancer cachectic
factor. Nature. 379:739–742. 1996. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Albrecht JT and Canada TW: Cachexia and
anorexia in malignancy. Hematol Oncol Clin North Am. 10:791–800.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mueller TC, Bachmann J, Prokopchuk O,
Friess H and Martignoni ME: Molecular pathways leading to loss of
skeletal muscle mass in cancer cachexia - can findings from animal
models be translated to humans? BMC Cancer. 16:752016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bodine SC, Latres E, Baumhueter S, Lai VK,
Nunez L, Clarke BA, Poueymirou WT, Panaro FJ, Na E, Dharmarajan K,
et al: Identification of ubiquitin ligases required for skeletal
muscle atrophy. Science. 294:1704–1708. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cai D, Frantz JD, Tawa NE Jr, Melendez PA,
Oh BC, Lidov HG, Hasselgren PO, Frontera WR, Lee J, Glass DJ and
Shoelson SE: IKKbeta/NF-kappaB activation causes severe muscle
wasting in mice. Cell. 119:285–298. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Clarke BA, Drujan D, Willis MS, Murphy LO,
Corpina RA, Burova E, Rakhilin SV, Stitt TN, Patterson C, Latres E
and Glass DJ: The E3 Ligase MuRF1 degrades myosin heavy chain
protein in dexamethasone-treated skeletal muscle. Cell Metab.
6:376–385. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Carson JA and Baltgalvis KA: Interleukin 6
as a key regulator of muscle mass during cachexia. Exerc Sport Sci
Rev. 38:168–176. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sun M, Ye Y, Xiao L, Duan X, Zhang Y and
Zhang H: Anticancer effects of ginsenoside Rg3 (Review). Int J Mol
Med. 39:507–518. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Li B, Wan L, Li Y, Yu Q, Chen P, Gan R,
Yang Q, Han Y and Guo C: Baicalin, a component of Scutellaria
baicalensis, alleviates anorexia and inhibits skeletal muscle
atrophy in experimental cancer cachexia. Tumour Biol.
35:12415–12425. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Van Gammeren D, Damrauer JS, Jackman RW
and Kandarian SC: The IkappaB kinases IKKalpha and IKKbeta are
necessary and sufficient for skeletal muscle atrophy. FASEB J.
23:362–370. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hayden MS and Ghosh S: Shared principles
in NF-kappaB signaling. Cell. 132:344–362. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Willis MS, Rojas M, Li L, Selzman CH, Tang
RH, Stansfield WE, Rodriguez JE, Glass DJ and Patterson C: Muscle
ring finger 1 mediates cardiac atrophy in vivo. Am J Physiol Heart
Circ Physiol. 296:H997–H1006. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Egerman MA and Glass DJ: Signaling
pathways controlling skeletal muscle mass. Cric Rev Biochem Mol
Biol. 49:59–68. 2014. View Article : Google Scholar
|
|
30
|
Waddell DS, Baehr LM, van den Brandt J,
Johnsen SA, Reichardt HM, Furlow JD and Bodine SC: The
glucocorticoid receptor and FOXO1 synergistically activate the
skeletal muscle atrophy-associated MuRF1 gene. Am J Physiol
Endocrinol Metab. 295:E785–E797. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Stitt TN, Drujan D, Clarke BA, Panaro F,
Timofeyva Y, Kline WO, Gonzalez M, Yancopoulos GD and Glass DJ: The
IGF-1/PI3K/Akt pathway prevents expression of muscle
atrophy-induced ubiquitin ligases by inhibiting FOXO transcription
factors. Mol Cell. 14:395–403. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sacheck JM, Ohtsuka A, McLary SC and
Goldberg AL: IGF-I stimulates muscle growth by suppressing protein
breakdown and expression of atrophy-related ubiquitin ligases,
atrogin-1 and MuRF1. Am J Physiol Endocrinol Metab. 287:E591–E601.
2004. View Article : Google Scholar : PubMed/NCBI
|
